Analysis of angiogenesis markers, circulating tumour, endothelial progenitor, endothelial, dendritic, T and B cells in women receiving adjuvant chemotherapy for early breast cancer
Not Applicable
Not yet recruiting
- Conditions
- Breast CancerCancer - Breast
- Registration Number
- ACTRN12605000732684
- Lead Sponsor
- Mater Adult hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
Patients receiving adjuvant chemotherapy for early breast cancer.
Exclusion Criteria
No exclusion criteria
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link angiogenesis markers to chemotherapy response in early breast cancer?
How do circulating tumour cells correlate with endothelial progenitor cell dynamics during adjuvant chemotherapy for breast cancer?
Which biomarkers in dendritic, T and B cell profiles predict prognosis for early breast cancer patients undergoing chemotherapy?
What adverse events are associated with adjuvant chemotherapy in early breast cancer and how are they managed?
Are there combination therapies targeting angiogenesis and immune cells that improve outcomes in early breast cancer compared to standard adjuvant chemotherapy?